ACOG committee opinion: Tamoxifen and endometrial cancer.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000175:diagnosis*; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D013629:Tamoxifen / Q000009:adverse effects*; D014481:United States
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen